Geron Corp (GERN): Cutting PT From $6 To $5 - FBR

September 13, 2016 7:56 AM EDT
Get Alerts GERN Hot Sheet
Price: $1.92 -3.52%

Rating Summary:
    5 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade GERN Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

FBR Capital analyst, Thomas Yip, reiterated his Outperform rating on shares of Geron Corporation (NASDAQ: GERN) but cut his price target to $5 from $6 based on amendments to the Phase II IMbark trial of imetelstat for the treatment of myelofibrosis (MF). The reduced PT is due to a higher clinical risk for imetelstat and a six-month delay of the projected approval for the MF indication (from late 2021 to mid-2022).

Despite the discontinued low dose arm (4.7 mg/kg), the analyst anticipates IMbark to go on with high dose imetelstat (9.4 mg/kg) without delay.

For an analyst ratings summary and ratings history on Geron Corporation click here. For more ratings news on Geron Corporation click here.

Shares of Geron Corporation closed at $2.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Add Your Comment